Ultragenyx Pharmaceutical (RARE) Q1 2025 Earnings
Ultragenyx Pharmaceutical reported Q1 2025 revenue of $139.3M (+28.0% YoY), missed analyst consensus of $162.4M by $23.1M. Diluted EPS came in at $-1.57 (+22.7% YoY), missed the $-1.54 consensus by $0.03.
Financial Snapshot
Trailing eight quarters through Q1 2025
Q1 2025 Earnings FAQ
Common questions about Ultragenyx Pharmaceutical's Q1 2025 earnings report.
Ultragenyx Pharmaceutical (RARE) reported Q1 2025 earnings on May 6, 2025 after market close.
Ultragenyx Pharmaceutical reported revenue of $139.3M and diluted EPS of $-1.57 for Q1 2025.
Revenue missed the consensus estimate of $162.4M by $23.1M. EPS missed the consensus estimate of $-1.54 by $0.03.
Compared to the same quarter a year prior, revenue grew 28.0% from $108.8M a year earlier and diluted EPS grew 22.7% from $-2.03.
You can read the 10-Q periodic report (0000950170-25-064726) directly on SEC EDGAR. The filing index links above go to sec.gov.